Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Legend Biotech

Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.

Arcellx stock reversed lower Monday on positive results for its rival to Legend Biotech's multiple myeloma treatment, Carvykti.

Investors Business Daily

Legend Biotech Reverses After J&J-Tied Cancer Drug Cuts Risk Of Death By 45%

Legend Biotech Reverses After J&J-Tied Cancer Drug Cuts Risk Of Death By 45%

Legend Biotech reversed early gains Monday after the company said its J&J-tied multiple myeloma drug, Cavykti, cut the risk of death.

Investors Business Daily

Legend Breaks Out After Leaked Documents Show Promise In $9.6 Billion Market

Legend Breaks Out After Leaked Documents Show Promise In $9.6 Billion Market

Legend Biotech is staring down a $9.6 billion opportunity, an analyst said Wednesday as LEGN stock soared on positive cancer test results.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022

Legend Biotech Stock Joins Elite Club Of Stocks With RS Ratings Over 90

Legend Biotech Corp sees its Relative Strength Rating enter the elite 90-plus level.

Investors Business Daily

Dow Jones Up As Powell Gives This Recession Warning; Bitcoin Crumbles Again; 3 Stocks Eye Buy Points

The Dow Jones rose despite a recession warning from Fed Chair Jerome Powell. Bitcoin tumbled again. Apple stock rose after a bullish call.

Investors Business Daily

The Daily Biotech Pulse: Setback For NRx Pharma's COVID Study, Fast Track Tag For Pfizer's NASH Combo Therapy, Reata's Ataxia Drug In FDA Review

Here's a roundup of top developments in the biotech space over the last 24 hours:

inkl

Read news from The Economist, FT, and more,
with one subscription

Analyst Ratings For Legend Biotech

Analyst Ratings For Legend Biotech

Analysts have provided the following ratings for Legend Biotech (NASDAQ:LEGN) within the last quarter:

GenScript Losses Widen, But Investors Focus on Newly Approved Cancer Treatment

GenScript Losses Widen, But Investors Focus on Newly Approved Cancer Treatment

Key takeaways: GenScript Biotech said it lost up to $519 million last year, with its Legend Biotech unit accounting for nearly 70% of that Legend Biotech’s Cilta-cel CAR-T cell therapy product was approved by the FDA on Monday, and could become a major cash cow for GenScript Biotech By Molly…

The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution

The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution

Here's a roundup of top developments in the biotech space over the last 24 hours:

FDA Approves JNJ-Legend Biotech Partnered Blood Cancer Therapy

FDA Approves JNJ-Legend Biotech Partnered Blood Cancer Therapy

FDA Slams Brakes On Legend Biotech's CAR-T Therapy Trial In Lymphoma Patients

FDA Slams Brakes On Legend Biotech's CAR-T Therapy Trial In Lymphoma Patients

The FDA has instituted a clinical hold on Legend Biotech Corporation's (NASDAQ:

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

Johnson & Johnson (

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

290,207 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play